Catalyst Pharmaceuticals Wins Zacks Rank #1, 46.4% Growth, 2037 Patent Protections
Catalyst Pharmaceuticals holds a Zacks Rank #1 and Value Score A after meeting low-PEG screening criteria with a PEG ratio below industry median and discounted P/E. The commercial-stage biopharma’s long-term historical growth rate stands at 46.4% and its Firdapse orphan therapy is protected by patents through 2037.
1. Screening Methodology
Catalyst Pharmaceuticals met a low-PEG screen requiring PEG ratios below the industry median, P/E ratios under peer benchmarks, Zacks Rank #1 or #2 eligibility, market capitalization above $1 billion and average 20-day volume over 50,000 shares.
2. Business Focus
The company is a commercial-stage biopharmaceutical entity concentrated on orphan and rare disease therapies, primarily generating revenue from Firdapse (amifampridine phosphate) under U.S. license through 2037 with approvals in multiple markets.
3. Financial Profile
Holding a Zacks Rank #1 and a Value Score A, Catalyst Pharmaceuticals exhibits a long-term historical earnings growth rate of 46.4%, reflecting its rapid commercial expansion and sustained investor interest.